eprintid: 10064487
rev_number: 21
eprint_status: archive
userid: 608
dir: disk0/10/06/44/87
datestamp: 2018-12-19 15:07:46
lastmod: 2021-10-24 23:23:09
status_changed: 2018-12-19 15:07:46
type: article
metadata_visibility: show
creators_name: Donker Kaat, L
creators_name: Meeter, LH
creators_name: Chiu, WZ
creators_name: Melhem, S
creators_name: Boon, AJW
creators_name: Blennow, K
creators_name: Zetterberg, H
creators_name: van Swieten, JC
title: Serum neurofilament light chain in progressive supranuclear palsy
ispublished: pub
divisions: UCL
divisions: B02
divisions: C07
divisions: D07
divisions: F86
keywords: Biomarker, Neurofilament, Progressive supranuclear palsy
note: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
abstract: INTRODUCTION: Neurofilament light chain (NfL) is a promising biomarker in neurodegenerative diseases. Elevated NfL levels in CSF and blood have been observed in a growing number of neurodegenerative disorders, including frontotemporal dementia and Alzheimer's disease. We studied serum NfL levels in patients with progressive supranuclear palsy (PSP) in relation to disease severity and survival. METHODS: Serum NfL levels were determined cross-sectionally in a retrospective cohort of 131 patients with PSP and 95 healthy controls. Detailed clinical examination was performed and disease severity was assessed by several rating scales. RESULTS: We found that serum NfL levels in PSP were twice as high as those in controls, and that NfL levels correlated with worse functional, motor and cognitive functioning. During follow-up, 119 PSP patients had died, and higher NfL levels were associated with a shorter survival. CONCLUSION: This study provides evidence that serum NfL is a relevant and promising biomarker in PSP for disease severity, and may be used as a prognostic tool to predict survival in clinical practice.
date: 2018-11
date_type: published
official_url: https://doi.org/10.1016/j.parkreldis.2018.06.018
oa_status: green
full_text_type: other
language: eng
primo: open
primo_central: open_green
article_type_text: Journal Article
verified: verified_manual
elements_id: 1564592
doi: 10.1016/j.parkreldis.2018.06.018
pii: S1353-8020(18)30277-3
language_elements: English
lyricists_name: Zetterberg, Henrik
lyricists_id: HZETT94
actors_name: Zetterberg, Henrik
actors_name: Harriot, Anne-Marie
actors_id: HZETT94
actors_id: AHARA72
actors_role: owner
actors_role: impersonator
full_text_status: public
publication: Parkinsonism & Related Disorders
volume: 56
pagerange: 98-101
event_location: England
issn: 1353-8020
citation:        Donker Kaat, L;    Meeter, LH;    Chiu, WZ;    Melhem, S;    Boon, AJW;    Blennow, K;    Zetterberg, H;           Donker Kaat, L;  Meeter, LH;  Chiu, WZ;  Melhem, S;  Boon, AJW;  Blennow, K;  Zetterberg, H;  van Swieten, JC;   - view fewer <#>    (2018)    Serum neurofilament light chain in progressive supranuclear palsy.                   Parkinsonism & Related Disorders , 56    pp. 98-101.    10.1016/j.parkreldis.2018.06.018 <https://doi.org/10.1016/j.parkreldis.2018.06.018>.       Green open access   
 
document_url: https://discovery.ucl.ac.uk/id/eprint/10064487/1/Zetterberg_Serum%20neurofilament%20light%20chain%20in%20progressive%20supranuclear%20palsy_AAM.pdf